C3L-00009
— · cohortA1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA1
- subtype
- cohortA1
- age_years
- 76.57221081
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.460
- ANGIOGENESIS+0.420
- PROTEIN_SECRETION+0.380
- KRAS_SIGNALING_UP+0.330
- PANCREAS_BETA_CELLS+0.320
- COAGULATION+0.310
- TGF_BETA_SIGNALING+0.270
- HYPOXIA+0.260
- UV_RESPONSE_DN+0.260
- IL6_JAK_STAT3_SIGNALING+0.240
Top 10 suppressed
- MYC_TARGETS_V2-0.480
- WNT_BETA_CATENIN_SIGNALING-0.330
- APICAL_SURFACE-0.270
- INTERFERON_ALPHA_RESPONSE-0.250
- CHOLESTEROL_HOMEOSTASIS-0.230
- INTERFERON_GAMMA_RESPONSE-0.230
- UNFOLDED_PROTEIN_RESPONSE-0.210
- DNA_REPAIR-0.190
- E2F_TARGETS-0.190
- G2M_CHECKPOINT-0.190
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR8518171 | — | A | 0.748 |
| 2 | SRR8518396 | — | A | 0.745 |
| 3 | TCGA-44-3398-01A-01R-1107-07 | — | cohortA1 | 0.723 |
| 4 | GSM6454743 | — | A | 0.720 |
| 5 | C3L-02345 | — | cohortA4 | 0.710 |
| 6 | TCGA-44-4112-01A-01R-1107-07 | — | cohortA1 | 0.708 |
| 7 | 2aefe8ef-5ffd-4c0d-8550-2573eb6fb051 | — | — | 0.703 |
| 8 | SRR35579842 | — | A | 0.690 |
| 9 | SRR6013569 | — | cohortMD2 | 0.690 |
| 10 | TCGA-BT-A20R-01A-12R-A16R-07 | — | — | 0.688 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 24 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.460 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.420 | Remibrutinib | — uncovered |
| PROTEIN_SECRETION | 0.380 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_UP | 0.330 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.320 | Cobimetinib | — uncovered |
| COAGULATION | 0.310 | Binimetinib | — uncovered |
| TGF_BETA_SIGNALING | 0.270 | Inavolisib | — uncovered |
| HYPOXIA | 0.260 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.260 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.240 | Inavolisib | — uncovered |
| COMPLEMENT | 0.220 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.190 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.190 | Remibrutinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.170 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.160 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.140 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.130 | Inavolisib | — uncovered |
| MYOGENESIS | 0.130 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.120 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.100 | Inavolisib | — uncovered |